Microplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI)

Status: Recruiting
Location: See all (10) locations...
Study Type: Observational
SUMMARY

Air pollution and microplastics pose major public health threats. Emerging data have shown that micro- and nanoplastics (MNPs) are ubiquitous environmental pollutants accumulating in human tissues, triggering inflammation and prothrombotic state. This study will investigate the presence and burden of MNPs within coronary thrombi/thromboaspirate of patients presenting with ST segment elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention and their association with cardiac damage, plaque vulnerability, microvascular obstruction, and cardiovascular events. Plaque vulnerability will be explored by optical coherence tomography, while microvascular obstruction will be assessed by bolus thermodilution and cardiac magnetic resonance. Participants will be followed up for 1-year to evaluate whether the presence and the burden of MNPs will be associated with a higher incidence of the cardiovascular events.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ All the following inclusion criteria should be fulfilled:

• Age \> 18 years old;

• STEMI undergoing urgent invasive coronary angiography;

• Acute thrombotic coronary occlusion/sub-occlusion (TIMI 0/1);

• Clinical indication to thromboaspiration;

• Able to give informed consent.

Locations
Other Locations
Italy
Department of Environmental Biological and Pharmaceutical Sciences and Technologies, University of Campania Luigi Vanvitelli
ACTIVE_NOT_RECRUITING
Caserta
Division of Cardiology, A.O.R.N. Sant'Anna e San Sebastiano, Caserta, Italy.
NOT_YET_RECRUITING
Caserta
Cardiovascular Department, A.O.U. Policlinico G. Rodolico - San Marco, University of Catania, Catania, Italy.
NOT_YET_RECRUITING
Catania
Azienda Ospedaliero Universitaria di Ferrara, Cona, Italy
NOT_YET_RECRUITING
Ferrara
Cardiovascular Division, Morgagni-Pierantoni University Hospital, Forlì, Italy.
NOT_YET_RECRUITING
Forlì
Interventional Cardiology Unit, De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy.
NOT_YET_RECRUITING
Milan
Department of Advanced Medical and Surgical Sciences, University of Campania-Luigi Vanvitelli, Naples, Italy.
ACTIVE_NOT_RECRUITING
Naples
Sant'Andrea University Hospital
RECRUITING
Roma
Division of Cardiology, Cardiovascular and Thoracic Department, Città della Salute e della Scienza, Turin, Italy.
NOT_YET_RECRUITING
Turin
Azienda Ospedaliera Integrata Verona, Italy
RECRUITING
Verona
Contact Information
Primary
Emanuele Barbato, MD, PhD
emanuele.barbato@uniroma1.it
+39 0633776115
Backup
Clinical Research Unit Cardiology Dept. Sant'Andrea University Hospital
cru.cardiologia@uniroma1.it
+39 0633778763
Time Frame
Start Date: 2025-04-22
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 130
Treatments
STEMI patients with presence of micro- and nano-plastics (MNPs).
Consecutive patients with ST-elevation myocardial infarction (STEMI) undergoing urgent invasive coronary angiography with evidence of acute thrombotic coronary occlusion/sub-occlusion and clinical indication to thromboaspiration with the presence of micro- and nano-plastics (MNPs).
STEMI patients without presence of micro- and nano-plastics (MNPs)
Consecutive patients with ST-elevation myocardial infarction (STEMI) undergoing urgent invasive coronary angiography with evidence of acute thrombotic coronary occlusion/sub-occlusion and clinical indication to thromboaspiration without the presence of micro- and nano-plastics (MNPs).
Sponsors
Collaborators: Morgagni Pierantoni Hospital, Azienda Ospedaliera Universitaria Integrata Verona, University Hospital, Catania, Niguarda Hospital, A.O.U. Città della Salute e della Scienza - Molinette Hospital, University of Campania Luigi Vanvitelli, Azienda Ospedaliera Universitaria Ferrara, Azienda Ospedaliera Sant'Anna e San Sebastiano
Leads: Azienda Ospedaliera Sant'Andrea

This content was sourced from clinicaltrials.gov